Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Hematological Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 0 results

Early research (Phase 1)UnknownNCT03588598
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)B-Cell Non-Hodgkin Lymphomas(NHL)
Nanjing Sanhome Pharmaceutical, Co., Ltd. 40
Early research (Phase 1)Looking for participantsNCT05476770
What this trial is testing

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAMLALL+8 more
Therapeutic Advances in Childhood Leukemia Consortium 54
Early research (Phase 1)Study completedNCT01844869
What this trial is testing

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Who this might be right for
Hematologic MalignanciesSolid Tumors
Teva Branded Pharmaceutical Products R&D, Inc. 6
Early research (Phase 1)Looking for participantsNCT07715630
What this trial is testing

In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Chongqing Precision Biotech Co., Ltd 15